AtCor Medical (ACG), the developer and marketer of the SphygmoCor® system which measures central blood pressures and arterial stiffness non-invasively announced that it has signed a new US$265,000 contract with a major international pharmaceutical company. This is an extension to an existing contract to supply SphygmoCor systems and clinical trials support services. A large portion of the contract value will be recognised in the current financial year.
During the past 120 days, AtCor has signed US$1.53m in new pharmaceutical contracts. The company has an ongoing pipeline of new business opportunities and anticipates additional pharmaceutical contracts in the current financial year.
“This contract extension has been awarded well in advance of contract expiration,” said Duncan Ross, CEO of AtCor Medical. “The new agreement demonstrates that AtCor’s growing reputation for high levels of customer satisfaction is being recognised through expanded business with long-term clients, and reinforces AtCor’s strong market position as the leading provider of non-invasive central blood pressure measurement in clinical trials.
With the US Healthcare Reform legislation now having been signed into law, the uncertainty as to key provisions and how they may affect the pharmaceutical industry has been clarified. AtCor expects this to translate into improved deal flow from this sector.
Tags: ACG, AtCor Medical, Healthcare, New contract
